- Do you have an innovative and transformative idea?
- Results and capabilities portfolio
- Collaborative innovation
- Funded Innovation Projects
- Up to date in innovation
- Biopolo La Fe - Business collaboration space
Pancreatic-miRaCan-VTE
- Area:
- Oncology and Hematology
- Group:
- Hemostasis, Thrombosis, Ateriosclerosis and Vascular biology
- Type:
- Software
Open web page available for researcher all around the world. Just upload a file with the expression level of these 7 miRNAs (miR-486-5p, miR-106b-5p, let-7i-5p, let-7g-5p, miR-144-3p, miR-19a-3p and miR-103a-3p) in your patients and our statistical model will rapidly calculate the risk of future VTE events in your PDAC and DECC patients.
Click here to access Pancreatic-miRaCan-VTE
Pancreatic-miRaCan-VTE is intended to be used for research purposes only, without any medical objective.
Cancer-associated venous thromboembolism (VTE) increases mortality and morbidity. However, limited tools are available to identify high risk patients. We propose miRNAs as new biomarkers to predict VTE in pancreatic ductal adenocarcinoma (PDAC) and distal extrahepatic cholangiocarcinoma (DECC). We have identified and confirmed a profile of 7 miRNAs able to estimate the risk of future VTE events in PDAC and DECC patients at diagnosis.
Further information about the methodological approach can be obtained in our article Oto, J, et al.(2020)